Literature DB >> 7027924

Chemoprophylaxis with cefoxitin and cephalothin in orthopedic surgery: a comparison.

M B Rosenfeld, J Campos, K R Ratzan, I Uredo.   

Abstract

Forty-eight patients who underwent elective hip or knee surgery were randomly divided into two groups. A total of 22 patients received a single 1-g preoperative bolus of cefoxitin, and 26 patients received a single 1-g preoperative dose of cephalothin. At various time intervals, serum and bone samples were taken during the operative procedure. Our data indicated that whereas serum levels of cefoxitin and cephalothin were maintained for at least 2h at levels capable of inhibiting most gram-positive cocci and many gram-negative rods, bone levels of cefoxitin rather rapid decay over a 2-h period. Moreover, in only 58% of the entire cephalothin-treated group were bone levels detectable and then only at a concentration that would inhibited gram-positive cocci. No significant morbidity was observed in either treatment group.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7027924      PMCID: PMC181530          DOI: 10.1128/AAC.19.5.826

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  The penetration characteristics of cefazolin, cephalothin, and cephradine into bone in patients undergoing total hip replacement.

Authors:  B A Cunha; H R Gossling; H S Pasternak; C H Nightingale; R Quintiliani
Journal:  J Bone Joint Surg Am       Date:  1977-10       Impact factor: 5.284

2.  Prophylactic antibiotics in clean orthopaedic surgery.

Authors:  A Pavel; R L Smith; A Ballard; I J Larsen
Journal:  J Bone Joint Surg Am       Date:  1974-06       Impact factor: 5.284

3.  A double-blind clinical trial of prophylactic antibiotics in hip fractures.

Authors:  R J Boyd; J F Burke; T Colton
Journal:  J Bone Joint Surg Am       Date:  1973-09       Impact factor: 5.284

4.  Antibiotic concentrations in human bone. A preliminary report.

Authors:  M C Kolczun; C L Nelson; M C McHenry; T L Gavan; P Pinovich
Journal:  J Bone Joint Surg Am       Date:  1974-03       Impact factor: 5.284

5.  Cloxacillin in the prophylaxis of postoperative infections of the hip.

Authors:  C Ericson; L Lidgren; L Lindberg
Journal:  J Bone Joint Surg Am       Date:  1973-06       Impact factor: 5.284

6.  Comparative bacteriology of early and late orthopedic infections.

Authors:  C Mitchell; M G Ehrlich; R S Siffert
Journal:  Clin Orthop Relat Res       Date:  1973-10       Impact factor: 4.176

7.  Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics.

Authors:  L D Sabath; C Garner; C Wilcox; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

8.  Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins.

Authors:  J J Schrogie; J D Rogers; K C Yeh; R O Davies; G I Holmes; H Skeggs; C M Martin
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

9.  Comparison of the antibacterial activity of nine cephalosporins against Enterobacteriaceae and nonfermentative gram-negative bacilli.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  The effect of hypotensive anesthesia on cephalothin concentrations in bone and muscle of patients undergoing total hip replacement.

Authors:  D Patel; R C Moellering; K Thrasher; N R Fahmy; W H Harris
Journal:  J Bone Joint Surg Am       Date:  1979-06       Impact factor: 5.284

View more
  2 in total

1.  Antibiotic prophylaxis in orthopedic surgery; has the time to reconsider the current practice arrived?

Authors:  Elisha Krasin; Yaniv Warschawski; Samuel Morgan; Michal Dekel
Journal:  J Orthop       Date:  2022-05-13

2.  Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy?

Authors:  Elias Polykandriotis; Raymund E Horch; Matthias Jost; Andreas Arkudas; Frieder Kees; Marweh Schmitz
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.